Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Sep 03, 2018 12:11pm
160 Views
Post# 28555972

RE:RE:taimed

RE:RE:taimed
SPCEO1 wrote:
muslix1 wrote:
what about whit taimed - 5.91%... no news ....


The news was that Taimed reported August Trogarzo sales - 23.3 million Taiwan dollars versus 13.0 million in July and 7 million in June. I like the trend but I guess the folks in Taiwan exepected more. I think expectations for sales in Taiwan must be higher than in North America.



Taimed's sales numbers just dont seem to make any sense from what we think we know from a patient number perspective. We thought we had 200 patients. We've had a month of supposed patient number growth since then and this purchase should support prescriptions through August.
 
TaiMed will manufacture and supply ibalizumab to Theratechnologies at a transfer price of 52% (+10%) of net sales of the product.
 
Net sales price is something like 600-700USD (is this wildly inaccurate???). So transfer price 350 USD per vial.
 
23million TWD is around $760,000 USD
 
So that translates as around 2000 vial
 
Pre-existing patients use 8 vials per month
New patients use 14 vials in the first month
 
So 2000 vials covers 
 
250 existing patients for the month of August
Or say 200 existing patients and 25 new patients
Or any other way you'd like to slice it
 
However you do slice it these Tiamed sales numbers just dont seem to support much growth in patient numbers in fact they look like the rate of patient acquisition has slowed since the report of 200 patients at the start of July. I guess there could be previous stocks in the system which could cover additional patients but all the previous sales numbers dont really support the idea that there is much of that. These sales numbers seem to suggest maybe 250 patients at the end of the August.
 
Or lets try it another way 
 
Taimed sales are 43,300,000 TWD for the Q (JJA) according to SPCEO here. That's 62% of gross sales. That works out at 3million CAD in gross sales for the Q if all Taimeds sales to Theratech in the Q are converted to sales to patients. Fred's 6million sales look far off.
 
Taimed's sales figures never seem to make much sense WRT what (little) Theratech say about patient numbers. Do people have a different take on this?
Bullboard Posts